Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Digital Health Meets AI -CSE: ALEN.U (click to learn more) New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more) Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Regen Biopharma Inc (ID) RGBPP

Healthcare Biotechnology
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News ()

Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025   

GlobeNewswire September 23, 2025

Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

GlobeNewswire September 16, 2025

Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression

GlobeNewswire September 4, 2025

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

GlobeNewswire August 15, 2025

Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product

GlobeNewswire July 23, 2025

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate(TM)

GlobeNewswire November 19, 2024

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time

GlobeNewswire September 23, 2024

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024

PR Newswire May 7, 2024

Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024

PR Newswire April 2, 2024
View More News ››

Opinion & Analysis ()

No current opinion is available.
View More Opinion ››

Bullboard Posts ()

Be the first to post on this bullboard.

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts